A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.

Also called NCT07278830

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 214 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07278830
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07278830. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-02 (actual); primary completion 2024-05-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia
Condition
Hypercholesterolemia and Mixed Dyslipidemia
Intervention (Drug)
SAL003 140mg+Atorvastatin
Intervention (Drug)
SAL003 420mg+Atorvastatin
Intervention (Drug)
Placebo 140mg+Atorvastatin
Intervention (Drug)
Placebo 420mg+Atorvastatin
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)
Collaborator
Salubris (Chengdu) Biotechnology Co., Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct07278830
Content hash
3ff6492941aabd44c4b9fde1d69a2328d0fc49c09accf20d31aed46ec7b79ac1